Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/19291
Full metadata record
DC FieldValueLanguage
dc.rights.licenseCC0 1.0 Universal*
dc.contributor.authorAntonijević, Marko-
dc.contributor.authorKosović Perutović, Milica-
dc.contributor.authorLeka, Zorica-
dc.contributor.authorMarković, Zoran-
dc.date.accessioned2023-11-06T07:40:35Z-
dc.date.available2023-11-06T07:40:35Z-
dc.date.issued2023-
dc.identifier.isbn9788682172024en_US
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/19291-
dc.description.abstractCarbonic anhydrases (CA) have been identified in the early ‘50s as potential targets for the treatment of numerous diseases, including cancer, glaucoma, epilepsy, etc. Current inhibitors, i.e., treatment options, offer high efficacy coupled with a high probability of various side-effects. On the other hand, dithiocarbamates and their metal complexes are known for being good CA inhibitors. In this paper, a novel Fe (II) dithiocarbamato complex was investigated for its biological and pharmacological properties using a combination of different in silico methodologies. It was found that this water soluble, almost non-toxic (LD50 values around 4860 mg/kg), druglike compound shows high inhibitory potential towards CA II. However, it also shows slow gastro-intestinal absorption, which means that, if ever used as a pharmacological agent, in its present form cannot be orally administrated. Binding energies with the value of -7.8 kcal mol-1 indicate reversible binding to human serum albumin, which can serve as a delivery system for the investigated compound. Overall, the obtained results indicate a high potential of (NH4)4[Fe(idadtc)2] to be an effective CA II inhibitor.en_US
dc.language.isoenen_US
dc.publisherUniversity of Kragujevac, Institute for Information Technologiesen_US
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.source2nd International Conference on Chemo and BioInformaticsen_US
dc.subjectDithiocarbamatesen_US
dc.subjectCarbonic anhydraseen_US
dc.subjectAlbuminen_US
dc.subjectADMETen_US
dc.subjectAcetazolamideen_US
dc.titleExploring the Pharmacokinetic Properties of (NH4)4[Fe(idadtc)2]: In Silico Biological screening and ADMET analysisen_US
dc.typeconferenceObjecten_US
dc.description.versionPublisheden_US
dc.identifier.doi10.46793/ICCBI23.213Aen_US
dc.type.versionPublishedVersionen_US
Appears in Collections:Institute for Information Technologies, Kragujevac

Page views(s)

368

Downloads(s)

45

Files in This Item:
File Description SizeFormat 
2nd-ICCBIKG- str 213-216.pdf502.06 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons